NO20045505L - Nye derivater av androstan og androsten med askorbinsyre og anvendelse derav ved behandling eller hindring av forskjellige tilstander, sykdommer og forstyrrelser - Google Patents

Nye derivater av androstan og androsten med askorbinsyre og anvendelse derav ved behandling eller hindring av forskjellige tilstander, sykdommer og forstyrrelser

Info

Publication number
NO20045505L
NO20045505L NO20045505A NO20045505A NO20045505L NO 20045505 L NO20045505 L NO 20045505L NO 20045505 A NO20045505 A NO 20045505A NO 20045505 A NO20045505 A NO 20045505A NO 20045505 L NO20045505 L NO 20045505L
Authority
NO
Norway
Prior art keywords
ascorbic acid
androsten
androstan
disorders
diseases
Prior art date
Application number
NO20045505A
Other languages
English (en)
Inventor
James P Kutney
Hongming Chen
Duanjie Hou
Changqing Wang
Original Assignee
Forbes Medi Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi Tech Inc filed Critical Forbes Medi Tech Inc
Publication of NO20045505L publication Critical patent/NO20045505L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer nye derivater som innbefatter forbindelser i androstan- og androstenseriene, koplet med askorbinsyre, som inkluder salter derav, og representert ved en eller flere av de generelle formlene: hvori R1, R2, R3, R4, R5, R6 kan velges individuelt fra hydrogen, OH, karbonyl, og en askorbyldel; og R7 kan være hydrogen eller et hvilket som helst halogen.
NO20045505A 2002-06-06 2004-12-16 Nye derivater av androstan og androsten med askorbinsyre og anvendelse derav ved behandling eller hindring av forskjellige tilstander, sykdommer og forstyrrelser NO20045505L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/165,769 US20030232797A1 (en) 2002-06-06 2002-06-06 Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders
PCT/CA2003/000824 WO2003104254A2 (en) 2002-06-06 2003-06-06 Novel derivatives of androstane and androstene with ascorbic a cid and use thereof in treating or preventing various conditions, diseases, and disorders

Publications (1)

Publication Number Publication Date
NO20045505L true NO20045505L (no) 2005-03-04

Family

ID=29732091

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045505A NO20045505L (no) 2002-06-06 2004-12-16 Nye derivater av androstan og androsten med askorbinsyre og anvendelse derav ved behandling eller hindring av forskjellige tilstander, sykdommer og forstyrrelser

Country Status (12)

Country Link
US (1) US20030232797A1 (no)
EP (1) EP1513862A2 (no)
JP (1) JP2005535611A (no)
KR (1) KR20050009737A (no)
CN (1) CN1774444A (no)
AU (1) AU2003232542A1 (no)
BR (1) BR0311622A (no)
CA (1) CA2488618A1 (no)
NO (1) NO20045505L (no)
NZ (1) NZ537053A (no)
RU (1) RU2004139094A (no)
WO (1) WO2003104254A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080015174A1 (en) * 1998-11-24 2008-01-17 Reading Christopher L Metabolic Disease Treatments
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
DE60045751D1 (de) 1999-09-30 2011-04-28 Harbor Biosciences Inc Therapeutische Behandlung androgenrezeptorbedingter Leiden
WO2005042692A2 (en) * 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
US20050234025A1 (en) * 2004-04-20 2005-10-20 Forbes Medi-Tech Inc. Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof
ATE519379T1 (de) * 2004-12-09 2011-08-15 Eurark Llc Produkt und verfahren zur herstellung eines mittels zur oralen verabreichung von nutrazeutika
GB0908174D0 (en) * 2009-05-13 2009-06-24 Isis Innovation Steroid containing composition and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4000397A1 (de) * 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
CA2139549A1 (en) * 1994-01-28 1995-07-29 Kazumi Ogata Corticoid derivatives and pharmaceutical and cosmetic compositions
KR100711861B1 (ko) * 1999-06-23 2007-04-25 포비스 메디-테크 인코포레이티드 심혈관질환을 치료하거나 예방하기 위한 피토스테롤 또는 피토스타놀과 아스코르브산의 결합체 및 그 용도
WO2003026672A1 (en) * 2001-09-26 2003-04-03 Forbes Medi-Tech Inc. A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl)
FR2831440B1 (fr) * 2001-10-25 2003-12-26 Oreal Composition cosmetique, renfermant un derive de la dhea et un agent apaisant

Also Published As

Publication number Publication date
KR20050009737A (ko) 2005-01-25
BR0311622A (pt) 2005-03-01
WO2003104254A3 (en) 2004-05-06
EP1513862A2 (en) 2005-03-16
US20030232797A1 (en) 2003-12-18
CN1774444A (zh) 2006-05-17
NZ537053A (en) 2007-11-30
WO2003104254A2 (en) 2003-12-18
CA2488618A1 (en) 2003-12-18
RU2004139094A (ru) 2005-08-10
AU2003232542A1 (en) 2003-12-22
JP2005535611A (ja) 2005-11-24

Similar Documents

Publication Publication Date Title
NO20064282L (no) Morfolinforbindelser
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CY1110745T1 (el) Παραγωγα πυρρολιδονης ως αναστολεις μαοβ
NO20062983L (no) Sulfonamid-derivater for behandling av sykdommer
ATE454380T1 (de) Organische verbindungen zur behandlung entzündlicher oder allergischer leiden
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
MY129796A (en) Novel anti-inflammatory androstane derivatives
ATE368031T1 (de) Neue gamma secretase inhibitoren
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
NO20055219L (no) Nye forbindelser
MXPA05009535A (es) Compuestos de acido n - alquil - hidroxamico - isoindolilo y sus usos farmaceuticos.
ATE273992T1 (de) Konjugate von ascorbinsäure und phytosterolen oder phytostanolen und ihre verwendung zur behandlung von gefässkrankheiten
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
CY1108808T1 (el) Ενωσεις μοτιλιδης
BR0312882A (pt) Derivados de pleuromutilina como antimicrobianos
HRP20090112T3 (en) 2- (1h-indolylsulfanyl) -aryl amine derivatives for use in the treatment of affective disorders, pain, adhd and stress urinary incontinence
GB0314967D0 (en) Piperazine derivatives
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
NO20045505L (no) Nye derivater av androstan og androsten med askorbinsyre og anvendelse derav ved behandling eller hindring av forskjellige tilstander, sykdommer og forstyrrelser
DE60017128D1 (de) Aromatische und heterozyklische derivate von phytosterolen und/oder phytostanolen zur behandlung von gefässkrankheiten
ATE407126T1 (de) Herstellung von (s)-4-fluormethyl-dihydro-furan-2-on

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application